{{overview_title}}
{{overview_content}}
{{mechanism_title}}
{{mechanism_content}}
{{benefits_title}}
{{research_title}}
{{research_content}}
{{safety_title}}
{{safety_content}}
Recommended products
Research peptides selected for quality and purity:
Top Pick
GHK-Cu
Anti-Aging Compound
Test your knowledge
Quick quiz · 6 questions
Frequently Asked Questions
Is PT-141 the same thing as Vyleesi?
PT-141 and bremelanotide are names for the same molecule. Vyleesi is the FDA-approved brand-name pharmaceutical product containing bremelanotide, supplied as a 1.75 mg subcutaneous auto-injector for hypoactive sexual desire disorder in premenopausal women. PT-141 sold as a 'research peptide' is the same compound in principle, but it is not manufactured or quality-controlled to pharmaceutical standards and is not approved for human use. The two are chemically equivalent but very different in terms of regulation, quality assurance and safety oversight.
Does PT-141 work for men?
PT-141 was studied in men in earlier development, and its central, desire-focused mechanism is not inherently sex-specific. However, the FDA approval is limited to premenopausal women with hypoactive sexual desire disorder, so any use in men is off-label or research-only and has not been approved on the basis of confirmatory Phase III trials. Men experiencing sexual dysfunction should consult a clinician, who can determine whether the problem relates to desire, arousal or erectile function — distinctions that point to different and properly evaluated treatments.
How long does PT-141 take to work?
The approved Vyleesi protocol calls for subcutaneous injection at least 45 minutes before anticipated sexual activity, though some users adjust the timing based on individual response. Because PT-141 acts on central desire pathways rather than producing an immediate physical effect, it is taken on demand ahead of activity rather than at the moment it is needed. It should be used no more than once in any 24-hour period and no more than eight times per month, and clinicians typically reassess benefit after about eight weeks of use.
What is the most common side effect of PT-141?
Nausea is by far the most common side effect, reported by roughly 40% of participants in clinical trials and occasionally severe enough to cause discontinuation. It tends to be most pronounced after the first dose. Other frequent effects include flushing, headache and injection-site reactions. A pharmacologically important effect is a transient rise in blood pressure, which is why the drug is contraindicated in uncontrolled hypertension and cardiovascular disease, and why dosing frequency is limited.
Is PT-141 legal to buy?
The approved product, Vyleesi, is legal in the United States as a prescription medicine for its approved indication. PT-141 sold online as a 'research peptide' occupies a legal gray area and is prohibited or restricted in some jurisdictions; importing it can trigger customs issues. Such material is not quality-assured and may not match its label. Legal status varies by country and region, and competitive athletes should treat melanocortin agonists as problematic under anti-doping rules. Always verify the law in your jurisdiction and consult a healthcare professional.
Sources
- Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics & Gynecology.
- Clayton AH, Althof SE, Kingsberg S, et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health (London).
- Pfaus J, Giuliano F, Gelez H. (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function. The Journal of Sexual Medicine.
- Molinoff PB, Shadiack AM, Earle D, et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences.
- Dhillon S, Keam SJ. (2019). Bremelanotide: First Approval. Drugs.
- U.S. Food and Drug Administration (2019). Vyleesi (bremelanotide injection) Prescribing Information and Approval. FDA Drug Approvals.